Chemoradiation with or without brachytherapy for unresectable klatskin tumours: promising results from a prospective study
In HPB
By: Sastri SJ.
Contributor(s): Shivastava S | Goel M | Mehta S | Shetty N | Dharia T | Chaudhari S | Kalyani N | Engineer R | .
Material type:
ArticleSeries: Vol 17 Issues Suppl 2.Publisher: 2015Description: 249.Subject(s): Unresectable klatskin tumours | Brachytherapy | Chemoradiation | DDC classification:
In:
HPBSummary: Objectives: Klatskin tumours are rare tumours with
poor prognosis. The present study was undertaken to
evaluate outcomes in patients undergoing high dose
chemoradiation (CRT)+/-endobiliary brachytherapy
EBBT).
Methods: From Aug 2005 to July 2012, 65 patients
were included. Patients were treated with either EBBT
with high-dose-rate Iridium-192 (median dose: 14 Gy)
delivered through the PTBD catheter or CRT alone
(52.557.5 Gy/25 fractions with concurrent weekly
gemcitabine (300 mg/m2) or with a combination of
CRT and EBBT. Univariate and multivariate analysis
for factors impacting outcome was performed.
Results: Overall 22 (34%) received only EBBT, while
27 (41%) received both EBBT and CRT and 16 (25%)
recieved high dose CRT. A total of 42 patients had
complete (n = 21) and partial response (n = 21) Other
patients had stable or progressive disease. Peritoneum
(13 patients) and liver (n = 4) were commonest sites of
distant progression.
Median follow up for whole group was 9 months
(617.5
| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Articles
|
Tata Memorial Hospital | Available | AR16898 |
Objectives: Klatskin tumours are rare tumours with
poor prognosis. The present study was undertaken to
evaluate outcomes in patients undergoing high dose
chemoradiation (CRT)+/-endobiliary brachytherapy
EBBT).
Methods: From Aug 2005 to July 2012, 65 patients
were included. Patients were treated with either EBBT
with high-dose-rate Iridium-192 (median dose: 14 Gy)
delivered through the PTBD catheter or CRT alone
(52.557.5 Gy/25 fractions with concurrent weekly
gemcitabine (300 mg/m2) or with a combination of
CRT and EBBT. Univariate and multivariate analysis
for factors impacting outcome was performed.
Results: Overall 22 (34%) received only EBBT, while
27 (41%) received both EBBT and CRT and 16 (25%)
recieved high dose CRT. A total of 42 patients had
complete (n = 21) and partial response (n = 21) Other
patients had stable or progressive disease. Peritoneum
(13 patients) and liver (n = 4) were commonest sites of
distant progression.
Median follow up for whole group was 9 months
(617.5
There are no comments for this item.